Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET

Company Participants

Sujal Patel - Co-Founder & CEO

Anna Mowry - CFO

Parag Mallick - Co-Founder & Chief Scientific Officer

Conference Call Participants

Matt Kim - Jefferies

Stephanie Yan - Cowen & Company

Edmund Tu - Morgan Stanley

David Delahunt - Goldman Sachs

Operator

Thank you for standing by, and welcome to the Nautilus Q1 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. As a reminder, today’s conference call is being recorded.

I would now like to turn the conference over to your host, Mr. (Alex Khan), with Investor Relations. Sir, you may begin.

Unidentified Company Representative

Thank you. Earlier today, Nautilus released financial results for the quarter ended March 31, 2022. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investorrelations@nautilus.bio. Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO; Parag Mallick, Co-Founder and Chief Scientist; and Anna Mowry, Chief Financial Officer.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, May 3, 2022. With that, I'll turn the call over to Sujal.

Sujal Patel

Thanks, Alex. Good morning, and thank you to everyone for joining us on the call. Today, we'll review our results for the first quarter of 2022, and provide an update on a range of recent scientific and related activities. My remarks will be relatively brief, as Parag has much to share with you. I'll begin by thanking our teams in the Bay Area and Seattle for their dedication and hard work again this quarter. Because of their efforts, we've continued to make strong progress against our key scientific and business goals. Each scientific objective we reach, and each business milestone we achieve, gets us one step closer to our ultimate purpose of improving the lives and health of people around the world. By providing ubiquitous access to the proteome, we expect to expand countless research horizons, and enable boundless scientific exploration and discovery. Our team of scientific and engineering innovators, is fully aligned towards and committed to realizing these important objectives.